The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting the ongoing challenges in developing advanced oncology treatments, Merck and Gilead announced the discontinuation of their Phase 3 KEYNOTE-D46/EVOKE-03 study. The trial was investigating a combination therapy of Gilead's Trodelvy and Merck's Keytruda for patients with metastatic non-small cell lung cancer. According to reports, the decision to halt the study followed an update on the trial status regarding the combination therapy versus monotherapy.
This setback occurs as major pharmaceutical firms face pressure to bolster their R&D pipelines, with competitor AstraZeneca recently reporting mixed results in similar lung cancer trials per market data. From a financial perspective, Merck's Keytruda generated approximately $25 billion in revenue in 2023, serving as a portfolio cornerstone, while Gilead has been aiming to expand Trodelvy's indications beyond breast cancer to offset slowing antiviral sales (per corporate earnings reports).
Sign in to access this content
Sign InInvestors should monitor key technical levels for both stocks, with GILD closing at $129.16 and MRK at $120.79 (close June 5, 2026). Looking ahead, healthcare sector sentiment may be influenced by upcoming U.S. JOLTs job openings data, which could provide insights into labor costs and broader economic spending in the United States.